Suven Life Sciences : Schedule of Conference Call for Investors on February 7, 2023
January 31, 2023 at 01:27 am EST
Share
CSD/BSE&NSE/CC/2022-23
January 31, 2023
To
To
The Manager
The Manager
Department of Corporate Services
Listing Department
BSE Limited
National Stock Exchange of India Limited
25th Floor, P. J. Towers,
Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai - 400 001
Bandra (E), Mumbai - 400 051
Scrip Code: 543064
Scrip Symbol: SUVENPHAR
Dear Sir/Madam,
Sub: Schedule of Conference Call for Investors
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Tuesday, February 7, 2023 at 12:00 Noon
IST to discuss the Un-Audited Financial Results for the Q3 & 9M FY23, to be declared on
Registered Office: # 8-2-334 I SDE Serene Chambers I 3rd Floor I Road No.5
Avenue 7 I Banjara Hills I Hyderabad - 500034 I Telangana I India I CIN: L24299TG2018PLC128171
Tel: 91 40 2354 9414 /1142 /3311 I Fax: 91 40 2354 1152 I Email: info@suvenpharm.com I www.suvenpharm.com
Suven Pharmaceuticals Ltd to host Q3 & 9MFY23 Results Conference call on Tuesday, February 07, 2023 @ 12 noon
Suven Pharmaceuticals Ltd will be conducting a conference call to discuss its Q3 & 9MFY23 results performance. Suven Pharmaceuticals Ltd will be represented by members of the senior management team.
The conference call will be initiated with a brief discussion after which the floor will be opened for Q&As. The financial results will be announced earlier on February 06, 2023.
In order to pre-register: Copy this URL in your browser:
Suven Life Sciences Limited published this content on 31 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 January 2023 06:26:05 UTC.
Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.
SUVEN LIFE SCIENCES LIMITED 
